Ryosuke Uchibori

ORCID: 0000-0002-2412-4943
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Virus-based gene therapy research
  • CAR-T cell therapy research
  • Mesenchymal stem cell research
  • RNA Interference and Gene Delivery
  • RNA regulation and disease
  • Cancer-related molecular mechanisms research
  • Viral Infectious Diseases and Gene Expression in Insects
  • CRISPR and Genetic Engineering
  • Viral gastroenteritis research and epidemiology
  • Wound Healing and Treatments
  • MicroRNA in disease regulation
  • Immunotherapy and Immune Responses
  • Electrospun Nanofibers in Biomedical Applications
  • Animal Virus Infections Studies
  • Nanowire Synthesis and Applications
  • Pulmonary Hypertension Research and Treatments
  • Peptidase Inhibition and Analysis
  • Transplantation: Methods and Outcomes
  • Nanofabrication and Lithography Techniques
  • Neurogenesis and neuroplasticity mechanisms
  • bioluminescence and chemiluminescence research
  • Pleural and Pulmonary Diseases
  • Biopolymer Synthesis and Applications
  • Multiple Myeloma Research and Treatments
  • Neuroblastoma Research and Treatments

Jichi Medical University
2014-2024

Jichi Medical University Hospital
2024

Takara (Japan)
2014-2022

Osaka University
2012

Shinshu University
2007

National Center of Neurology and Psychiatry
2007

Ōtani University
2007

Saitama Cancer Center
2006

Abstract Background Mesenchymal stem cells (MSCs) are a promising vehicle for targeted cancer gene therapy because of their potential tumor tropism. For efficient therapeutic application, we developed retroviral vector‐producing MSCs that enhance transduction via progeny vector production. Methods Rat bone marrow‐derived were nucleofected with the proviral plasmids (vesicular stomatitis virus‐G protein‐pseudotyped components) (VP‐MSCs) or pLTR plasmid alone (non‐VP‐MSCs). The...

10.1002/jgm.1313 article EN The Journal of Gene Medicine 2009-03-09

Pulmonary arterial hypertension (PAH) is a fatal disease associated with inflammation and pathological remodeling of the pulmonary artery (PA). Interleukin (IL)-10 pleiotropic antiinflammatory cytokine vasculoprotective properties. Here, we report preventive effects IL-10 on monocrotaline-induced PAH. Three-week-old Wistar rats were intramuscularly injected an adeno-associated virus serotype 1 vector expressing IL-10, followed by monocrotaline injection at 7 weeks old. transduction...

10.1161/circresaha.107.153023 article EN Circulation Research 2007-08-03

In vivo gene transduction with adeno-associated virus (AAV)-based vectors depends on laborious procedures for the production of high-titer vector stocks. Purification steps efficient clearance impurities such as host cell proteins and empty particles are required to meet end-product specifications. Therefore, development alternative, realistic methods facilitate a scalable recovery procedure is critical promote in investigations. However, conventional purification resin-based packed-bed...

10.1089/hum.2009.006 article EN Human Gene Therapy 2009-06-17

Abstract Mesenchymal stem cells (MSC) accumulate at tumor sites when injected into tumor-bearing mice, perhaps offering cellular vectors for cancer-targeted gene therapy. However, the molecular mechanisms involved in MSC targeting tumors are presently little understood. We focused on MSC–endothelial cell (EC) adhesion following TNF-α stimulation an attempt to elucidate these mechanisms. Interestingly, of MSCs with enhanced endothelial vitro. This was partially inhibited by blocking...

10.1158/0008-5472.can-12-0088 article EN Cancer Research 2012-10-13

Recent studies have shown that stem cell memory T (TSCM) cell-like properties are important for successful adoptive immunotherapy by the chimeric antigen receptor-engineered-T (CAR-T) cells. We previously reported both human and murine-activated cells converted into memory-like (iTSCM) coculture with stromal OP9 expressing NOTCH ligand. However, mechanism of NOTCH-mediated iTSCM reprogramming remains to be elucidated. Here, we report NOTCH/OP9 system efficiently conventional CAR-T TSCM-like...

10.1158/0008-5472.can-19-1196 article EN Cancer Research 2019-11-25

The transduction of cancer cells using recombinant adeno-associated virus (rAAV) occurs with low efficiency, which limits its utility in gene therapy. We have previously sought to enhance rAAV-mediated by applying DNA-damaging stresses. In this study, we examined the effects histone deacetylase inhibitor FR901228 on tumor mediated rAAV types 2 and 5. treatment significantly improved expression transgene four cell lines. surface levels alpha v integrin, FGF-R1, PDGF-R were modestly enhanced...

10.1016/j.ymthe.2005.11.010 article EN cc-by-nc-nd Molecular Therapy 2006-01-05

Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder with limited therapeutic options. An aberrant wound healing process in response to repetitive lung injury has been suggested for its pathogenesis, and number of cytokines including transforming growth factor β1 play pivotal roles the induction progression fibrosis. Thus, regulation these pro-inflammatory conditions may reduce IPF ameliorate symptoms patients. Interleukin-10 (IL-10), pleiotropic cytokine, exerts...

10.1089/hum.2018.024 article EN Human Gene Therapy 2018-03-30

The major causative agent of cervical cancer is human papilloma virus (HPV); the viral proteins E6 and E7 induce carcinogenesis through inactivation host tumor-suppressor gene. Therefore, stable expression specific inhibitors in cells expected to provide effective treatment for without affecting normal tissue. In this study, we propose a novel therapeutic approach using an adeno-associated (AAV) vector encoding short hairpin RNA (shRNA) against oncoproteins (shE6E7) HPV type 16 (HPV‑16),...

10.3892/ijo.2018.4245 article EN cc-by-nc-nd International Journal of Oncology 2018-01-15

Adenovirus and adeno-associated virus (AAV) vectors are increasingly used for gene transduction experiments. However, to produce a sufficient amount of these in vivo experiments requires large-capacity tissue culture facilities, which may not be practical limited laboratory space. We describe here large-scale method adenovirus AAV with an active gassing system that uses large vessels process labor- cost-effective infection or transfection closed system. Development this was based on the 293...

10.1089/hum.2005.16.1212 article EN Human Gene Therapy 2005-10-01

Prostacyclin synthase (PGIS) is the final committed enzyme in metabolic pathway of prostacyclin production. The therapeutic option intravenous infusion patients with pulmonary arterial hypertension limited by short half-life drug and life-threatening catheter-related complications. To develop a better delivery system for prostacyclin, we examined feasibility intramuscular injection an adenoassociated virus (AAV) vector expressing PGIS preventing monocrotaline-induced rats. We developed AAV...

10.1161/hypertensionaha.107.091348 article EN Hypertension 2007-07-17

Adoptive transfer of T cells expressing a chimeric antigen receptor (CAR) is promising cell-based anticancer therapy. Although clinical studies this approach show therapeutic efficacy, additional genetic modification necessary to enhance the efficacy and safety CAR-T cells. For example, production an antitumor cytokine from can potentially their tumor-killing activity, but there are concerns that constitutive expression molecules will cause systemic side effects. Therefore, it important...

10.1016/j.omto.2018.11.003 article EN cc-by Molecular Therapy — Oncolytics 2018-12-01

Galanin and its receptors, GALR1 GALR2, are known tumor suppressors potential therapeutic targets in head neck squamous cell carcinoma (HNSCC). Previously, we demonstrated that, GALR1-expressing HNSCC cells, the addition of galanin suppressed proliferation via upregulation ERK1/2 cyclin-dependent kinase inhibitors, whereas, GALR2-expressing not only proliferation, but also induced apoptosis. In this study, first transduced HEp-2 KB lines using a recombinant adeno-associated virus...

10.1111/cas.12315 article EN cc-by-nc-nd Cancer Science 2013-10-30

Since renal cell carcinoma is considered an immunogenic tumor, testing therapeutic strategies has been impeded by the lack of relevant tumor models in immunocompetent animals. Recent advances bioluminescence imaging permit sensitive vivo detection and quantification cells emitting light. Thus, we established bioluminescent rat lines for rats.The line ACI-RCC stemming from chemically induced syngeneic ACI rats was stably transfected with a recombinant retroviral vector encoding luciferase...

10.1016/j.juro.2009.12.090 article EN The Journal of Urology 2010-03-23

The safety and high efficiency of adeno-associated virus (AAV) vectors has facilitated their wide-scale use to deliver therapeutic genes for experimental clinical purposes in diseases affecting the central nervous system (CNS). AAV1, 2, 5, 8, 9, rh10 are most commonly used serotypes CNS applications. Most AAVs known transduce predominantly into neurons. However, precise tropism dentate gyrus (DG), region where persistent neurogenesis occurs adult brain, is not fully understood. We...

10.1089/hum.2021.106 article EN Human Gene Therapy 2021-08-05

Abstract It is established that neurogenesis of dentate gyrus increased after ischemic insult, although the regulatory mechanisms have not yet been elucidated. In this study, we focused on Ezh2 which suppresses gene expression through catalyzing trimethylation lysine 27 histone 3. Male gerbils were injected with adeno-associated virus (AAV) carrying shRNA targeting to into right 2 weeks prior forebrain ischemia. One week ischemia, animals thymidine analogue label proliferating cells. Three...

10.1007/s12035-024-04200-w article EN cc-by Molecular Neurobiology 2024-04-27

CAR-T cell therapy targeting CD19 and BCMA for relapsed or refractory hematopoietic tumors has been adopted in routine practice shown dramatic results. However, half of patients who achieve remission with eventually relapse, thus efforts to improve the efficacy are gaining momentum. Notably, studies have described innovative technologies that enable control kinetics after infusion, which is not possible conventional therapies. In this article, we review challenges development new technologies.

10.11406/rinketsu.65.597 article EN PubMed 2024-01-01
Coming Soon ...